Johnson & Johnson (JNJ)

Close Price	Market Cap	P/E Ratio	Forward P/E Ratio	Implied Growth*	Implied Forward Growth*	Dividend	P/B Ratio
$225.33	$542.42B	26.1	17.7	14.5%	10.3%	$5.36 2.4%	6.7

Latest Headlines

· RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
· VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks
· Want $1,400 in Passive Income? Invest $10,000 Into These 4 Dividend Stocks
· New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma
· New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
· FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

Revenue & Net Income

	Date	Revenue	Net_Income	EPS	Last_Updated	Revenue_Change	Net_Income_Change	EPS_Change
0	2021-12-31	$78,740M	$20,878M	$7.93	2026-02-13 08:39:13	N/A	N/A	N/A
1	2022-12-31	$79,990M	$17,941M	$6.86	2026-05-29 09:09:42	1.6%	-14.1%	-13.5%
2	2023-12-31	$85,159M	$35,153M	$14.60	2026-05-29 09:09:42	6.5%	95.9%	112.8%
3	2024-12-31	$88,821M	$14,066M	$5.84	2026-05-29 09:09:42	4.3%	-60.0%	-60.0%
4	2025-12-31	$94,193M	$26,804M	$11.13	2026-05-29 09:09:42	6.0%	90.6%	90.5%
5	TTM 2026-03-31	$96,362M	$21,040M	$8.63	2026-04-24 08:44:54	2.3%	-21.5%	-22.5%

EPS

Forecasts

Y/Y % Change

YoY Growth Rates

JNJ Year-over-Year Growth

	2021	2022	2023	2024	2025	2026	2027	Average
Revenue Growth (%)		1.6%	6.5%	4.3%	6.0%	7.1%	6.3%	5.3%
Revenue Analysts (#)	0	0	0	0	0	21	23
EPS Growth (%)		-14.1%	95.9%	-60.0%	90.6%	4.0%	9.8%	21.0%
EPS Analysts (#)	0	0	0	0	0	25	25

Forward Estimate History

How the next-FY EPS and revenue estimates have drifted over time. One line per fiscal year – past lines end when that FY became current.

Forward revenue projection history by FY

Expenses

Year	Revenue ($)	Cost of Revenue ($)	R&D ($)	G&A ($)	SG&A ($)	Facilities / D&A ($)	Personnel ($)
2022	$80.0B	$17.6B	$14.1B	$20.2B	$20.2B	$7.0B	$-1.2B
2023	$85.2B	$19.1B	$15.1B	$21.5B	$21.5B	$7.5B	$-1.4B
2024	$88.8B	$20.1B	$17.2B	$22.9B	$22.9B	$7.3B	$-900.0M
2025	$94.2B	$22.8B	$14.7B	$0.0	$23.7B	$7.5B	$0.0
TTM	$96.4B	$23.3B	$15.0B	$11.8B	$24.6B	$7.7B	$-200.0M

Year	Revenue Change (%)	Cost of Revenue Change (%)	R&D Change (%)	G&A Change (%)	SG&A Change (%)	Facilities / D&A Change (%)	Personnel Change (%)
2023	6.46	8.18	6.72	6.25	6.25	7.40	16.67
2024	4.30	5.59	14.23	6.31	6.31	-1.96	-35.71
2025	6.05	13.02	-14.90	-100.00	3.53	2.23	-100.00
TTM	2.30	2.27	2.06	inf	3.89	3.09	-inf

No unmapped expenses.

Segment Performance

axis1_JNJ_I_N_V_E_G_A_S_U_S_T_E_N_N_A_X_E_P_L_I_O_N_T_R_I_N_Z_A_T_R_E_V_I_C_T_A.png

axis1_JNJ_P_R_E_Z_I_S_T_A_P_R_E_Z_C_O_B_I_X_R_E_Z_O_L_S_T_A_S_Y_M_T_U_Z_A.png

SEGMENTS v2025-09-09 · 2026-05-29 09:09 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).

Year	D A R Z A L E X Rev	Stelara Rev	G E N E R A L Rev	Tremfya Rev	A D V A N C E D Rev	I N V E G A S U S T E N N A X E P L I O N T R I N Z A T R E V I C T A Rev	C O N T A C T L E N S E S O T H E R Rev	Other Rev	T R A U M A Rev	I M B R U V I C A Rev	Xarelto Rev	Simponi Simponi Aria Rev	U P T R A V I Rev	Remicade Rev	H I P S Rev	P R E Z I S T A P R E Z C O B I X R E Z O L S T A S Y M T U Z A Rev	K N E E S Rev	C A R V Y K T I Rev	S U R G I C A L Rev	S P R A V A T O Rev	E D U R A N Trilpivirine Rev	O T H E R N E U R O S C I E N C E Rev	C O N C E R T A Methylphenidate Rev	R Y B R E V A N T L A Z C L U Z E Rev	Other Oncology Rev	T A L V E Y Rev	Other Infectious Diseases Rev	Other Immunology Rev	Abiomed Rev	C A P L Y T A Rev	E L E C T R O P H Y S I O L O G Y Rev	Erleada Rev	O P S U M I T Rev	Other Cardiovascular Rev	Other Pulmonary Hypertension Rev	S P I N E S P O R T S O T H E R Rev	Shockwave Medical Inc. Rev	T E C V A Y L I Rev	Z Y T I G A Rev	Total Rev
2023	19.5B	21.7B	10.7B	6.29B	9.34B	8.23B	7.40B	2.61B	5.96B	6.53B	4.73B	4.39B	3.16B	3.68B	3.12B	3.71B	2.91B	1.00B	2.74B	1.38B	2.30B	3.11B	1.57B	0.19B	0.66B	0.13B	2.83B	0.02B	2.61B	–	9.38B	4.77B	3.95B	0.71B	0.52B	5.89B	–	0.79B	1.77B	170.3B
2024	23.3B	20.7B	10.7B	7.34B	8.98B	8.44B	7.47B	2.38B	6.10B	6.08B	4.75B	4.38B	3.63B	3.21B	3.28B	3.42B	3.09B	1.93B	2.83B	2.15B	2.54B	2.35B	1.28B	0.65B	0.63B	0.57B	0.82B	0.01B	2.99B	–	10.5B	6.00B	4.45B	0.76B	0.48B	5.85B	1.13B	1.10B	1.26B	177.6B
2025	28.7B	12.2B	11.1B	10.3B	9.15B	7.62B	7.82B	2.29B	6.29B	5.65B	5.27B	5.34B	3.80B	3.54B	3.35B	3.16B	3.17B	3.77B	3.12B	3.39B	2.97B	2.10B	1.17B	1.47B	0.75B	0.93B	0.35B	0.12B	3.50B	1.40B	11.3B	7.15B	4.65B	0.79B	0.42B	5.70B	2.29B	1.34B	1.00B	188.4B
TTM	66.4B	37.4B	27.3B	22.8B	22.5B	19.9B	19.1B	17.5B	15.6B	14.5B	12.7B	12.3B	9.31B	8.52B	8.31B	8.27B	7.88B	7.63B	7.45B	7.12B	7.05B	5.52B	3.02B	2.92B	2.20B	1.98B	1.33B	0.22B	–	–	–	–	–	–	–	–	–	–	–	376.7B
% of Total (TTM)	17.6%	9.9%	7.2%	6.0%	6.0%	5.3%	5.1%	4.6%	4.1%	3.8%	3.4%	3.3%	2.5%	2.3%	2.2%	2.2%	2.1%	2.0%	2.0%	1.9%	1.9%	1.5%	0.8%	0.8%	0.6%	0.5%	0.4%	0.1%	–	–	–	–	–	–	–	–	–	–	–	100%

Segment Performance (Axis 2)